Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
暂无分享,去创建一个
I. Barroso | I. Farooqi | P. Clayton | T. Cheetham | E. Henning | R. Bounds | J. Keogh | E. Crowne | L. Wilson | J. Mokrosiński | Aliki Perdikari | A. Mcaulay | D. Jyothish | M. J | Farooqi Is | T. Randell | P. Partha | Edson Mendes de Oliveira | F. Talbot | R. Ahmed | Natalia Wasiluk | V. Ayinampudi | Sharon Lim | Sanjay Gupta | M. Kershaw | C. Matei | A. McAulay | Sharon Lim | Keogh Jm | Henning E | Bounds R | Ayinampudi V | Wasiluk N | Barroso I | Mendes de Oliveira E | Talbot F | Ahmed R | Perdikari A | Jyothish D | Lim S | Gupta S | Kershaw M | Matei C | Partha P | Randell T | McAulay A | Wilson Lc | Cheetham T | Crowne Ec | Clayton P
[1] W. Chung,et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. , 2020, The lancet. Diabetes & endocrinology.
[2] E. Zeggini,et al. Exome Sequencing Identifies Genes and Gene Sets Contributing to Severe Childhood Obesity, Linking PHIP Variants to Repressed POMC Transcription , 2020, Cell metabolism.
[3] E. Germain-Lee. Management of pseudohypoparathyroidism , 2019, Current opinion in pediatrics.
[4] Matthew W. Darlison,et al. Rare single gene disorders: estimating baseline prevalence and outcomes worldwide , 2018, Journal of Community Genetics.
[5] H. Jüppner,et al. Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early‐Onset Obesity , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] O. Mäkitie,et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement , 2018, Nature Reviews Endocrinology.
[7] K. Clément,et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency , 2018, Nature Medicine.
[8] Amita Sharma,et al. Early-Onset Obesity: Unrecognized First Evidence for GNAS Mutations and Methylation Changes , 2017, The Journal of clinical endocrinology and metabolism.
[9] K. Clément,et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency , 2017, Molecular metabolism.
[10] Tom R. Gaunt,et al. Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity , 2017, Scientific Reports.
[11] A. Mamoune,et al. Progressive Development of PTH Resistance in Patients With Inactivating Mutations on the Maternal Allele of GNAS , 2017, The Journal of clinical endocrinology and metabolism.
[12] M. Bastepe,et al. Heterotrimeric G proteins in the control of parathyroid hormone actions. , 2017, Journal of molecular endocrinology.
[13] H. Jüppner,et al. Pseudohypoparathyroidism: one gene, several syndromes , 2017, Journal of Endocrinological Investigation.
[14] P. Hindmarsh,et al. Pseudohypoparathyroidism Type 1A-Subclinical Hypothyroidism and Rapid Weight Gain as Early Clinical Signs: A Clinical Review of 10 Cases , 2016, Journal of clinical research in pediatric endocrinology.
[15] K. Clément,et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. , 2016, The New England journal of medicine.
[16] K. Okamura,et al. Complex Genomic Rearrangement Within the GNAS Region Associated With Familial Pseudohypoparathyroidism Type 1b. , 2016, The Journal of clinical endocrinology and metabolism.
[17] A. Linglart,et al. The Prevalence of GNAS Deficiency-Related Diseases in a Large Cohort of Patients Characterized by the EuroPHP Network. , 2016, The Journal of clinical endocrinology and metabolism.
[18] B. Zemel,et al. Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A. , 2016, The Journal of clinical endocrinology and metabolism.
[19] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[20] R. Thakker,et al. GNAS Mutations in Pseudohypoparathyroidism Type 1a and Related Disorders , 2014, Human mutation.
[21] H. Jüppner,et al. Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type Ic defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsα‐receptor interaction , 2011, Human mutation.
[22] S. O’Rahilly,et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. , 2011, The Journal of clinical endocrinology and metabolism.
[23] S. Mackem,et al. Parathyroid hormone/parathyroid hormone-related protein receptor signaling is required for maintenance of the growth plate in postnatal life , 2010, Proceedings of the National Academy of Sciences.
[24] O. Gavrilova,et al. Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. , 2009, Cell metabolism.
[25] M. Maghnie,et al. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. , 2007, The Journal of clinical endocrinology and metabolism.
[26] L. Weinstein,et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Levine,et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. , 2003, The Journal of clinical endocrinology and metabolism.
[28] Tim Cheetham,et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. , 2003, The New England journal of medicine.
[29] M. Saji,et al. Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. , 2002, Biochemical and biophysical research communications.
[30] A. Grüters,et al. Thyroid Function and Obesity in Children and Adolescents , 2001, Hormone Research in Paediatrics.
[31] P. Bougnères,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Resistance to the Lipolytic Action of Epinephrine: A New Feature of Protein G s Deficiency , 1999 .
[32] T J Cole,et al. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. , 1998, Statistics in medicine.
[33] R. Lasker,et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. , 1983, The American journal of medicine.
[34] S. O’Rahilly,et al. Modulation of blood pressure by central melanocortinergic pathways. , 2009, The New England journal of medicine.
[35] L. Weinstein,et al. The stimulatory G protein alpha-subunit Gs alpha is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. , 2003, The Journal of clinical endocrinology and metabolism.
[36] Min Chen,et al. Gs(alpha) mutations and imprinting defects in human disease. , 2002, Annals of the New York Academy of Sciences.
[37] L. Weinstein,et al. Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit. , 2002, Molecular endocrinology.
[38] D. Accili,et al. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.